Accuracy of a rapid intrapartum test for maternal group B streptococcal colonisation and its potential to reduce antibiotic usage in mothers with risk factors
Important Message: COVID-19
We are now home-based during the COVID-19 pandemic but available and working. Responses may however take longer than normal as staff may be working altered hours but we are cross covering trials as required and urgent matters will be dealt with promptly. Please do not contact our usual office/landline number and instead email the trial contact and copy in the trial mailbox. If a query requires a prompt response please mark as ‘urgent’ in the email subject header
Main Trial Features
- Prospective test accuracy study embedded within a cluster randomised controlled trial (CRT), and economic evaluation
- GBS2 is investigating the accuracy of a rapid test (Cepheid GeneXpert) for GBS colonisation among women presenting to a labour wards with risk factors associated with GBS transmission, comparing against the reference standard of selective enrichment culture, in a prospective cohort study
- We are also evaluating if rapid GBS testing reduces maternal and neonatal antibiotic usage, compared with usual care where administration of Intrapartum Antibiotic Prophylaxis (IAP) is directed based on maternal risk factors alone, in a cluster randomised trial
- Funded by the NIHR HTA (13/82/04)
- Chief Investigator Prof Shakila Thangaratinam
- Coordinated by Birmingham Clinical Trials Unit (BCTU)
- Sponsored by Queen Mary, University of London
- Award start: 1st May 2016, award end: 31st October 2019
- The trial finished recruitment on 30th April 2019 and the HTA report is currently under peer review.
Primary Contact: email@example.com or Trial Manager Emily Dixon firstname.lastname@example.org
Please use the link on the right for the latest GBS2 documentation.